Traws Pharma details $3,128,399 ATM capacity
Traws Pharma, Inc. reported that it may sell additional shares of common stock through its existing at-the-market equity program with Citizens JMP Securities, LLC.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Traws Pharma, Inc. reported that it may sell additional shares of common stock through its existing at-the-market equity program with Citizens JMP Securities, LLC. Under updated prospectus supplements, the company can offer shares having an aggregate offering price of up to $3,128,399, reflecting its current “baby shelf” limitation under General Instruction I.B.6. of Form S-3.
These sales would occur from time to time under the previously established At The Market Offering Agreement for up to $50,000,000 and rely on the company’s effective shelf registration statement on Form S-3 and related prospectus supplements.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
ATM program size: $50,000,000
Current baby shelf capacity: $3,128,399
Shelf registration number: 333-273081
+3 more
6 metrics
ATM program size
$50,000,000
Maximum aggregate sales price under At The Market Offering Agreement
Current baby shelf capacity
$3,128,399
Aggregate offering price of shares that may be sold under prospectus supplements
Shelf registration number
333-273081
Form S-3 registration statement covering ATM sales
Shelf filing date
June 30, 2023
Date Form S-3 shelf registration was filed
Shelf effective date
July 11, 2023
Date Form S-3 registration statement was declared effective
ATM Agreement date
March 10, 2025
Date At The Market Offering Agreement with Citizens JMP Securities, LLC was entered
Key Terms
At The Market Offering Agreement, shelf registration statement on Form S-3, baby shelf limitation, General Instruction I.B.6. of Form S-3, +1 more
5 terms
At The Market Offering Agreement financial
"the Company entered into an At The Market Offering Agreement (the “ATM Agreement”)"
An at-the-market offering agreement is a contract that lets a company sell newly issued shares directly into the open market through a broker, at whatever price the stock is trading at that moment. For investors this matters because it can increase the number of shares available (which may dilute existing ownership) while providing a flexible, often faster way for the company to raise cash without fixing a price, similar to a vendor selling small batches at current market stalls rather than setting a single fixed price.
shelf registration statement on Form S-3 regulatory
"effective shelf registration statement on Form S-3 and an accompanying prospectus"
A shelf registration statement on Form S-3 is a pre-approved filing with the Securities and Exchange Commission that lets an eligible public company register securities in advance and sell them later in one or more offerings without repeating the full registration process. Think of it like a pre-approved funding line: it gives management the flexibility to raise capital quickly when market conditions are right, a move that can affect share supply, dilution and investor returns, so investors monitor it as a signal of potential financing activity.
baby shelf limitation regulatory
"which is the Company’s current “baby shelf” limitation under General Instruction I.B.6."
General Instruction I.B.6. of Form S-3 regulatory
"current “baby shelf” limitation under General Instruction I.B.6. of Form S-3"
prospectus supplements financial
"as supplemented by those prospectus supplements dated March 10, 2025, April 7, 2025 and May 22, 2026"
A prospectus supplement is an official add-on to a securities prospectus that provides new or updated details about a specific stock, bond, or other offering, such as terms, risks, or financial data. Investors use it like a product label update—checking it tells them what exactly is being offered, any changes from the original plan, and whether the investment's risks, size, or price have shifted, which can affect buy, hold, or sell decisions.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Traws Pharma (TRAW) disclose in its latest 8-K filing?
Traws Pharma disclosed it may sell additional common stock under its existing at-the-market agreement. The company can offer shares with an aggregate offering price up to $3,128,399, using its effective Form S-3 shelf registration and related prospectus supplements filed with the SEC.
What is the size of Traws Pharma’s at-the-market equity program?
Traws Pharma’s At The Market Offering Agreement allows sales of common stock up to an aggregate sales price of $50,000,000. Actual current capacity under the baby shelf limitation is lower, at an aggregate offering price of up to $3,128,399 as described in the prospectus supplements.
Who is the sales agent for Traws Pharma’s at-the-market offering?
Citizens JMP Securities, LLC acts as sales agent and/or principal for Traws Pharma’s at-the-market program. The company may offer and sell shares of its common stock to or through Citizens from time to time under the existing At The Market Offering Agreement and effective shelf registration.
What is Traws Pharma’s current baby shelf limitation for TRAW stock?
Traws Pharma stated that, under the prospectus supplements, it may offer and sell common stock having an aggregate offering price of up to $3,128,399. This amount represents the company’s current baby shelf limitation under General Instruction I.B.6. of Form S-3 for its at-the-market program.
Which SEC registration statement covers Traws Pharma’s ATM sales?
The at-the-market sales are made under Traws Pharma’s effective shelf registration statement on Form S-3, Registration Statement No. 333-273081. It was filed with the SEC on June 30, 2023 and declared effective on July 11, 2023, together with related base prospectus and prospectus supplements.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates